HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unilever enters tech partnership

This article was originally published in The Rose Sheet

Executive Summary

Dove marketer has entered into a five-year partnership with Silicon Valley-based Ampere Life Sciences to access the firm's Digital Biology technology platform and secure exclusive rights for the development of innovative consumer products, U.K. firm announces Sept. 16. Unilever and Ampere scientists will work together on "the core biology of aging" for a "range of benefit areas of interest to Unilever," company says. Unilever Chief R&D Officer Genevieve Berger touts firms' "commitment to develop superior products across a number of categories and exclusivity that will potentially give us competitive advantage in the marketplace." Deal is in line with Unilever's "open innovation" approach, and such efforts will help the company meet consumer demand for healthy living as the market for aging products increases, firm notes. Though terms of the deal were not disclosed, work will begin immediately, the companies say. Unilever recently announced an undisclosed investment in Solazyme, a firm that produces renewable oil and bioproducts from algae that can be used as a substitute for petroleum and plant oils in personal-care products (1"The Rose Sheet" Sept. 20, 1010)

You may also be interested in...

Could Unilever Investment In Microalgae Solve Firm's Palm Oil Problems?

Unilever is reasserting its commitment to environmental sustainability with an undisclosed investment in Solazyme, the same company that is helping the U.S. Navy to reach its renewable fuel goals

Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal

Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.

Dr Reddy’s Enters Complicated Sensipar Market In US

Dr Reddy’s Laboratories has launched a generic version of Sensipar in the US, the former blockbuster to treat hyperparathyroidism, with originator Amgen having previously been involved in multiple intellectual property fights over agreements with ANDA sponsors Teva and Cipla.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts